Rocket Pharmaceuticals, Inc. (RCKT)
RCKTNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$2.55
+0.1650 (+6.92%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $277.73m
- P/E
- –
- EPS, last 4 quarters
- $-1.40
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.17 to $5.45
- Average volume
- 1.94m
- Previous close
- $2.39
Analysts
12 coveringHold7 buy, 5 hold, 0 sell
Targets a year out average $9.50, +272.5% from here
Earnings
next estimate $-0.3900Next report
Sep 2025
+6.3%
Dec 2025
+9.5%
Mar 2026
-2.4%
Jun 2026
-153.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$52.25m | -$43.96m | -$48.51m | -$46.92m |
| Net income | -$50.33m | -$42.54m | -$47.59m | $123.21m |
News
8 latest- Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral from SellFintel · Oct 8, 2026
- Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety ResetMarketBeat · Oct 6, 2026
- Needham Upgrades Rocket Pharmaceuticals to Buy from HoldFintel · Sep 16, 2026
- RCKT Aligns With FDA on Completing Phase II Study in Danon DiseaseZacks · Sep 16, 2026
- Rocket Gets FDA Nod To Advance RP-A501 Phase 2 Trial In Danon Disease; Stock Up RTTNews · Sep 15, 2026
- Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?Zacks · Sep 11, 2026
- Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?Zacks · Sep 10, 2026
- Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?Zacks · Sep 9, 2026
The company
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. Rocket's cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies, together representing one of the broadest pipelines focused on inherited heart disease. The Company's integrated platform combines proprietary adeno-associated virus (AAV) manufacturing capabilities and extensive clinical experience in cardiac gene therapy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- rocketpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.